Penningtons Manches Cooper Advised SkinBioTherapeutics Plc On £4.6 Million Fundraising On AIM

Penningtons Manches Cooper advised SkinBioTherapeutics plc on £4.6 million fundraising on AIM

Penningtons Manches Cooper is advised SkinBioTherapeutics plc (AIM: SBTX) on its £4.6 million equity fundraising through a placing, subscription, and a separate retail offer made to existing shareholders via the Winterflood Retail Access Platform.

This marks the fifth equity fundraising on AIM for which Penningtons Manches Cooper has advised its long-standing client, SkinBioTherapeutics. Singer Capital Markets is acting as nominated adviser and broker on the transaction, which is expected to close on June 24, 2025.

SkinBioTherapeutics is a UK-based life science company focused on skin health. On June 16, 2025, the company announced an exclusive UK commercial agreement with Superdrug Stores plc, one of the country’s leading health and beauty retailers, to distribute its AxisBiotix™ food supplements aimed at alleviating inflammatory skin conditions.

Net proceeds from the fundraising will be used to support the execution of the Superdrug agreement and for general working capital purposes.

The Penningtons Manches Cooper team is led by London-based corporate partner Seb Orton, with support from associate Jenny Wright.

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.